Naveen Pemmaraju
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Naveen Pemmaraju as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:37 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07128381 · Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center · recruiting · Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML) · principal investigator
- Ph1NCT06613217 · Study of Oral PCLX-001 in R/R Acute Myeloid LeukemiaPacylex Pharmaceuticals · recruiting · Relapsed Adult AML · principal investigator
- Ph2NCT04216524 · Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer Center · recruiting · Blastic Plasmacytoid Dendritic Cell Neoplasm · principal investigator
- Ph1NCT04022785 · PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm · principal investigator
- Ph2NCT02098161 · LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisM.D. Anderson Cancer Center · completed · Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT04216524, NCT04022785
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:37 UTC. The ranking covers the 200 most relevant of 113 PubMed records, and a shared surname and initials can bring in a namesake. All 113 on PubMed
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.Cancer Discov · 2019480 citationsRCR 15.8
- Ibrutinib and Venetoclax for First-Line Treatment of CLL.N Engl J Med · 2019426 citationsRCR 15.0
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med · 2019366 citationsRCR 13.0
- Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med · 2023357 citationsRCR 30.6
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- 221 citationsRCR 6.0
- 220 citationsRCR 6.7
- 210 citationsRCR 6.8
- 206 citationsRCR 5.5